Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of April 2026 for Clearmind Medicine Inc., a foreign private issuer headquartered in Vancouver, British Columbia. The filing details specific capital transactions involving convertible promissory notes entered into with CLA Investors.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific transaction metrics reported include:
- Promissory Note Issuance: On April 20, 2026, the Company issued notes with an aggregate principal amount of $2,700,000.
- Cash Proceeds: The aggregate purchase price paid in cash was $2,430,000 (90% of principal).
- Debt Conversion: On April 21, 2026, investors converted $2,680,029.60 of principal into 4,466,716 common shares.
Material Changes
The primary material change is the reduction of outstanding debt through conversion and the corresponding increase in outstanding common shares. This activity stems from a broader securities purchase agreement dated September 17, 2025, which authorized up to $10,000,000 in convertible notes.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation by reference into existing registration statements. The transaction was executed in accordance with the terms of the previously announced SPAs.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion (4,466,716 new shares issued).
- Confirm the remaining principal balance available under the $10,000,000 SPA facility.
- Review the conversion price implied by the transaction ($2,680,029.60 / 4,466,716 shares).
- Check subsequent filings for any remaining unconverted principal from the April 20 issuance.